What is the financial impact of the planned sale of the Consumer Healthcare business?

Pfizer has agreed to sell its Consumer Healthcare business for approximately $16.6 billion. This business has been reclassified to 'Discontinued operations - net of tax' in the financial statements. The divestiture is expected to close in late 2006, subject to regulatory approvals. This transaction will impact future revenue and expense reporting as the business will no longer be part of ongoing operations.

How is Pfizer managing the impact of patent expirations on its revenue?

Pfizer is actively managing the impact of patent expirations on key products like Neurontin, Zoloft, and Zithromax by focusing on its broad portfolio of patent-protected medicines and introducing new products. The company launched three new medicines in the U.S. in 2006 (Sutent, Eraxis, Chantix) and expects to launch Exubera. They are also investing in R&D and pursuing strategic acquisitions and collaborations to bolster the pipeline.

What is the Adapting to Scale (AtS) productivity initiative, and what is its financial impact?

The Adapting to Scale (AtS) initiative, launched in early 2005, is a company-wide effort to increase efficiency and streamline decision-making. It involves reorganizing R&D, optimizing manufacturing facilities, and reducing costs. In the second quarter of 2006, the company incurred $442 million in implementation and restructuring costs related to AtS. Pfizer expects total cost savings from this initiative to exceed $2 billion in 2006 and reach approximately $4 billion annually upon completion in 2008.

What were the significant acquisitions made during the period?

Pfizer completed two significant acquisitions in the first half of 2006. In May, they acquired Rinat Neuroscience Corp., a biologics company focused on central nervous system product candidates, recording $478 million in merger-related in-process R&D charges. In February, Pfizer acquired the worldwide rights to Exubera, an inhaled insulin, along with related production facilities, for approximately $1.4 billion. This acquisition resulted in the recording of a $1.0 billion intangible asset for developed technology rights.

PFE 10-Q Quarterly Report Q3 FY2006 — Revenue, Net Income, EPS

Summary

Pfizer Inc. reported its second-quarter 2006 financial results, showing a decrease in net income to $2.415 billion from $3.463 billion in the prior year's quarter. This decline was influenced by various factors, including the planned divestiture of the Consumer Healthcare business and other operational adjustments. Total revenues for the quarter increased by 3% year-over-year to $11.741 billion, driven by solid performance across the Human Health segment, particularly in key therapeutic areas like cardiovascular and central nervous system disorders. Significant strategic initiatives are underway, including the pending $16.6 billion sale of the Consumer Healthcare business, which has been reclassified as discontinued operations. The company also continues to execute its Adapting to Scale (AtS) productivity initiative, aiming for substantial cost savings. Investments in research and development remain robust, with new product launches like Sutent, Eraxis, and Chantix contributing to the pipeline. Despite facing patent expirations for key products, Pfizer is strategically positioning itself for future growth through pipeline development and targeted acquisitions.

Key Highlights

1Total revenues for Q2 2006 increased by 3% to $11.741 billion compared to Q2 2005.
2Net income decreased to $2.415 billion in Q2 2006 from $3.463 billion in Q2 2005.
3The company has entered into an agreement to sell its Consumer Healthcare business for approximately $16.6 billion, classifying it as discontinued operations.
4Research and Development (R&D) expenses decreased by 5% to $1.742 billion for the quarter compared to the prior year.
5Significant costs were incurred related to the Adapting to Scale (AtS) productivity initiative, with implementation and restructuring charges totaling $442 million in the quarter.
6Acquisitions during the period included Rinat Neuroscience Corp. for CNS product candidates and the sanofi-aventis worldwide rights to Exubera.
7The company repurchased shares, with $41.6 million shares purchased under the expanded share-purchase program in the quarter.

PFIZER INC Quarterly Report for Q3 Ended Jul 2, 2006

Summary

Key Highlights

Frequently Asked Questions